Antipsychotic drug interactions with specific [3H]ketanserin binding sites in membrane fragments derived from human prefrontal cortex and human amygdala.
Two regions of the brain potentially significant for psychopathology in schizophrenia are the prefrontal cortex and the amygdala. Antipsychotic compounds bind at serotonin receptors in human prefrontal cortex. We hypothesized that the serotoninergic antagonist [3H]ketanserin would label similar sets of binding sites in these two brain regions. Further, we hypothesized that all antipsychotic compounds would show appreciable affinity for binding sites labeled by [3H]ketanserin in the prefrontal cortex. Our findings indicate some differences in [3H]ketanserin binding between prefrontal cortex and amygdala. We also observed that several antipsychotic compounds had very high affinity for the [3H]ketanserin binding sites in prefrontal cortex.
Andorn
Anne C
AC
Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0431, USA. acandorn@utmb.edu
Bennett
Taffee L
TL
Gallagher
Kathleen K
KK
Hogan
Dale
D
D000679:Amygdala / Q000378:metabolism*; D014150:Antipsychotic Agents / Q000378:metabolism*; D001665:Binding Sites; D001667:Binding, Competitive; D002462:Cell Membrane / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D007650:Ketanserin / Q000378:metabolism*; D008875:Middle Aged; D017397:Prefrontal Cortex / Q000378:metabolism*; D011869:Radioligand Assay; D012702:Serotonin Antagonists / Q000378:metabolism*
D014150:Antipsychotic Agents; D012702:Serotonin Antagonists; D007650:Ketanserin